Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Online drug retailer DocMorris trims 2023 outlook

Published 19/10/2023, 06:46
© Reuters.
DOCM
-

By Tristan Veyet and Mateusz Dobrzyniewski

(Reuters) - Swiss online drug retailer DocMorris said it expected its annual loss to be at the upper end of a previous forecast, driving its shares down by more than 10% on Thursday following a decline in paper prescriptions.

It forecast an adjusted core loss of 30 million to 40 million Swiss francs ($33.4 million to $44.5 million) in 2023, compared to the previous range of 20-40 million.

The company, which relies heavily on the German market since it sold its Swiss business to Migros earlier this year, still aims to become profitable in 2024. This target does not take into account the positive effect of e-prescriptions, which were rolled out across Germany in July.

Revenues based on paper prescriptions declined by 16.9% in local currency, DocMorris said, adding that was below expectations.

DocMorris also cut its 2023 external revenue outlook, expecting a high single-digit percentage decline in local currency, from a previously expected mid-single-digit drop.

Its external revenue fell by 5.8% to 256 million Swiss francs in the third quarter, below the 262 million francs expected by analysts polled by the company.

"In 3Q23, DocMorris clearly underperformed its closest competitor Redcare Pharmacy," Baader Helvea said in a research note.

Redcare Pharmacy earlier in October said its third quarter sales rose by two thirds, aided by double-digit growth in sales of non-prescription products.

But analysts said DocMorris had weighed on the wider sector and Redcare Pharmacy's shares fell around 3% on Thursday.

($1 = 0.8990 Swiss francs)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.